Severe Sirolimus-Related Inflammatory State Anemia in an HIV+ Liver Transplant Patient With Calcineurin Inhibitor Renal Insufficiency: A Case Report

Transplantation Proceedings

Volumn 40, Issue 10, 2008, Pages 3810-3812

  Moreno, A ^a   Barcena R ^a   Garcia Gonzalez M ^a   Garcia Hoz F ^a   Quereda, C ^a   Casado, J L ^a   Perez Elias M J ^a   Fortun J ^a   Nuno J ^a   Arranz, I ^a   Moreno, S ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; C REACTIVE PROTEIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; ERYTHROPOIETIN; FIBRINOGEN; HEMOGLOBIN; IRON; LAMIVUDINE; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; STAVUDINE; TACROLIMUS;

ADULT; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; DIGESTIVE TRACT ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GRAFT RECIPIENT; GRAFT REJECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MEAN CORPUSCULAR VOLUME; METABOLIC ACIDOSIS; PRIORITY JOURNAL;

ANEMIA; BLOOD TRANSFUSION; C-REACTIVE PROTEIN; CALCINEURIN; ERYTHROPOIETIN; HIV SEROPOSITIVITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; IRON; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SIROLIMUS; TRANSFERRIN;

EID: 57549092882     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.07.130     Document Type: Article

References (24)

1. Moreno A., Bárcena R., Quereda C., et al. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation. AIDS 22 (2008) 547
2. Gonwa T.A., Mai M.L., Melton L.B., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 72 (2001) 1934
3. Miró J., Montejo M., Castells L., et al. Prognostic factors of mortality in HCV/HIV-co-infected liver transplant recipients: the FIPSE OLT-HIV-05-GESIDA 45-05 Cohort Study (2008) Program and Abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, February 3-6, (Abstract 1062)
4. Miró J.M., Aguero F., Laguno M., et al. Liver transplantation in HIV/hepatitis coinfection. J HIV Ther 12 (2007) 24
5. Buhaescu I., Izzedine H., and Covic A. Sirolimus-challenging current perspectives. Ther Drug Monit 28 (2006) 577
6. Morard I., Dumortier J., Spahr L., et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 13 (2007) 658
7. Roy J., Paquette J.S., Fortin J.F., et al. The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 46 (2002) 3447
8. Gilliam B., Heredia A., DeVico A., et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS 21 (2007) 2108
9. Maheshwari A., Mishra R., and Thuluvath P.J. Post-liver transplant anemia: etiology and management. Liver Transpl 10 (2004) 165
10. Morelon E., and Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 35 3 suppl (2003) 52S
11. Thaunat O., Beaumont C., Chatenoud L., et al. Anemia after late introduction of sirolimus may correlate with biochemical evidence of a chronic inflammatory state. Transplantation 80 (2005) 1212
12. Mehrabi A., Fonouni H., Kashfi A., et al. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 20 suppl 17 (2006) 30
13. Neff G.W., Montalbano M., Slapak-Green G., et al. A retrospective review of sirolimus (Rapamune) therapy in orthotopic liver transplant recipients diagnosed with chronic rejection. Liver Transpl 9 (2003) 477
14. Zhou J., Fan J., Wang Z., et al. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: report of an initial experience. World J Gastroenterol 12 (2006) 3114
15. Maheshwari A., Torbenson M.S., and Thuluvath P.J. Sirolimus monotherapy versus sirolimus in combination with steroids and/or MMF for immunosuppression after liver transplantation. Dig Dis Sci 51 (2006) 1677
16. Toso C., Meeberg G.A., Bigam D.L., et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83 (2007) 1162
17. Augustine J.J., Knauss T.C., Schulak J.A., et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 4 (2004) 2001
18. Sánchez Fructuoso A., Calvo N., Moreno M.A., et al. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transpl Proc 39 (2007) 2242
19. Maiorano A., Stallone G., Schena A., et al. Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation 82 (2006) 908
20. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011
21. Kim M.J., Mayr M., Pechula M., et al. Marked erythrocyte microcytosis under primary immunosuppression with sirolimus. Transplant Int 19 (2006) 12
22. Kassahun K., McIntosh I., Cui D., et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus integrase 1 enzyme. Drug Metab Dispos 35 (2007) 1657
23. Friend P., Russ G., Oberbauer R., et al. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function. Transpl Int 20 (2007) 754
24. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoietin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085